Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Samsung Biologics Co.,Ltd.    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
11/17/2020 11/18/2020 11/19/2020 11/20/2020 11/23/2020 Date
774000 812000 808000 799000 804000 Last
202653 403930 183400 120168 102510 Volume
+2.11% +4.91% -0.49% -1.11% +0.63% Change
Financials
Sales 2019 602 B 0,54 B 0,54 B
Net income 2019 44,8 B 0,04 B 0,04 B
Net cash position 2019 237 B 0,21 B 0,21 B
P/E ratio 2019 1 230x
Yield 2019 0,01%
Sales 2020 1 057 B 0,95 B 0,95 B
Net income 2020 232 B 0,21 B 0,21 B
Net cash position 2020 250 B 0,23 B 0,23 B
P/E ratio 2020 229x
Yield 2020 -
Capitalization 53 197 B 47 663 M 47 983 M
EV / Sales 2019 88 372x
EV / Sales 2020 50 316x
Nbr of Employees 2 534
Free-Float 24,9%
More Financials
Company
SAMSUNG BIOLOGICS CO.,LTD. is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops, manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Samsung Biologics Co.,Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about SAMSUNG BIOLOGICS CO.,LTD.
11/18FDA Accepts Biogen, Samsung Bioepis Filing for Lucentis Biosimilar
DJ
11/18S.Korea shares rise on hopes of Fed's policy support; rising virus cases weig..
RE
11/16Samsung BioLogics says mass producing Eli Lilly's COVID-19 treatment
RE
11/16SAMSUNG BIOLOGICS : says mass producing Eli Lilly's COVID-19 treatments
RE
11/05CHECKPOINT THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Recen..
AQ
11/03CHECKPOINT THERAPEUTICS : Samsung Biologics and Checkpoint Therapeutics Expand M..
AQ
10/27How Samsung's ownership may change as heirs take over from late Chairman Lee
RE
10/25Lee's death sparks hope for Samsung shake-up, dividends
RE
10/22Trial begins in Samsung leader Jay Y. Lee's suspected fraud, stock manipulati..
RE
10/06EMA Accepts Biogen, Samsung Bioepis Filing for Lucentis Biosimilar
DJ
09/03Samsung's Future Includes a $2 Billion 'Super Plant' -- Update
DJ
09/03Samsung's Drugmaking Future Includes a $2 Billion 'Super Plant' Bigger Than t..
DJ
09/01Samsung leader Jay Y. Lee indicted in South Korea on allegations linked to 20..
RE
09/01SAMSUNG ELECTRONICS : Lee indicted over controversial 2015 merger
AQ
09/01REFILE-UPDATE 3-Samsung leader Jay Y. Lee indicted in S.Korea on allegations ..
RE
More news
News in other languages on SAMSUNG BIOLOGICS CO.,LTD.
06/04Samsung-Erbe Lee droht wegen Manipulationsvorwürfen die Verhaftung
05/26Samsung-Erbe Lee wird wegen umstrittener Firmenfusion vernommen
2019CORÉE DU SUD : mandats d'arrêt contre deux vice-présidents de Samsung Electronic..
2018Résumé des principales informations économiques du mercredi 14 novembre 2018
2018Samsung BioLogics accusé de 4 milliards de dollars d'irrégularités comptables
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 804 000,00 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Tae-Han Kim Chief Executive Officer & Director
Ho-Yeol Yoon Managing Director & Head-Operations Support
James J. Choi Managing Director & Head-Information Technology
Yong-Ho An Managing Director & Head-Process Technology
Dong-Joong Kim Director & Head-Management Support
Sector and Competitors
1st jan.Capitalization (M$)
SAMSUNG BIOLOGICS CO.,LTD.85.68%47 663
CSL LIMITED14.84%104 855
BIOGEN INC.-17.98%37 452
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.153.87%30 660
ALEXION PHARMACEUTICALS, INC.12.23%26 833
UCB28.91%20 401